# Top 10 population extracts from Θεραπευτικά_Πρωτόκολλα_ΕΟΠΕ-10η_Έκδοση_cleaned.json

=== Ranked Population 1 (Extract #7, Patients) — Score: 9 ===
2;11:193, x.
33.Kudo M, Finn RS, Qin S et al; Lenvatinib versus sorafenib in first-line treatment of patients with
unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar
34.Bruix J, Qin S, Merle P, Granito A et al ; RESORCE Investigators. Regorafenib for patients with
hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-
blind, placebo-controlled, phase 3 trial. Lancet. 2017 Jan 7;389(10064):56-66. Epub 2016 Dec 6
35.Abou-Alfa GK, Meyer T, Cheng AL et al ; Cabozantinib in patients with advanced and progressing
hepat

=== Ranked Population 2 (Extract #8, Patients) — Score: 9 ===
ORCE Investigators. Regorafenib for patients with
hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-
blind, placebo-controlled, phase 3 trial. Lancet. 2017 Jan 7;389(10064):56-66. Epub 2016 Dec 6
35.Abou-Alfa GK, Meyer T, Cheng AL et al ; Cabozantinib in patients with advanced and progressing
hepatocellular carcinoma. N Engl J Med. 2018 Jul 5;379(1):54-63
36.Zhu AX, Kang YK, Yen CJ ae al , ; REACH-2 study investigators. Ramucirumab after sorafenib in patients
with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a
rand

=== Ranked Population 3 (Extract #9, Patients) — Score: 9 ===
Jan 7;389(10064):56-66. Epub 2016 Dec 6
35.Abou-Alfa GK, Meyer T, Cheng AL et al ; Cabozantinib in patients with advanced and progressing
hepatocellular carcinoma. N Engl J Med. 2018 Jul 5;379(1):54-63
36.Zhu AX, Kang YK, Yen CJ ae al , ; REACH-2 study investigators. Ramucirumab after sorafenib in patients
with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a
randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Feb;20(2):282-296.
37.El-Khoueiry AB, Sangro B, Yau T et al; Nivolumab in patients with advanced hepatocellular carcinoma
(C

=== Ranked Population 4 (Extract #10, Patients) — Score: 9 ===
stigators. Ramucirumab after sorafenib in patients
with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a
randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Feb;20(2):282-296.
37.El-Khoueiry AB, Sangro B, Yau T et al; Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet.
2017 Jun 24;389(10088):2492-2502.
38.Zhu AX, Finn RS, Edeline J et al; KEYNOTE-224 investigators. Pembrolizumab in patients with advanced
hepatocellular car

=== Ranked Population 5 (Extract #18, Patients) — Score: 9 ===
th cancer, especially that attributable to cancer
treatment. Health Technol Assess 2007;11:1-202.
5. Ludwig H, Van Belle S, Barrett-Lee, et al The European Cancer Anaemia Survey (ECAS): a large,
multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in
cancer patients. Eur J Cancer 2004;40:2293-2306.
6. Jabbour E, Kantarjian HM, Koller C, Taher A Red blood cell transfusions and iron overload in the
treatment of patients with myelodysplastic syndromes. Cancer 2008;112:1089-1095.
7. Birgegård G, Gascón P, Ludwig H. Evaluation of anaemia in patients with multiple m

=== Ranked Population 6 (Extract #19, Patients) — Score: 9 ===
Cancer Anaemia Survey (ECAS): a large,
multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in
cancer patients. Eur J Cancer 2004;40:2293-2306.
6. Jabbour E, Kantarjian HM, Koller C, Taher A Red blood cell transfusions and iron overload in the
treatment of patients with myelodysplastic syndromes. Cancer 2008;112:1089-1095.
7. Birgegård G, Gascón P, Ludwig H. Evaluation of anaemia in patients with multiple myeloma and
lymphoma: findings of the European Cander Anaemia Survey. Eur J Haematol 2006;77:378-386.
8.  (last accessed 8 May 2009).
9. Harper P, Littlewoo

=== Ranked Population 7 (Extract #20, Patients) — Score: 9 ===
aemia in
cancer patients. Eur J Cancer 2004;40:2293-2306.
6. Jabbour E, Kantarjian HM, Koller C, Taher A Red blood cell transfusions and iron overload in the
treatment of patients with myelodysplastic syndromes. Cancer 2008;112:1089-1095.
7. Birgegård G, Gascón P, Ludwig H. Evaluation of anaemia in patients with multiple myeloma and
lymphoma: findings of the European Cander Anaemia Survey. Eur J Haematol 2006;77:378-386.
8.  (last accessed 8 May 2009).
9. Harper P, Littlewood T. Anaemia of cancer: impact on patient fatigue and long-term outcome.
Oncology 2005;69 Suppl 2:2-7.
αρχική εκτίμηση και η περι

=== Ranked Population 8 (Extract #27, Patients) — Score: 9 ===
10. Nicolatou-Galitis O, Papadopoulou E, Vardas E, et al (2020) Alveolar bone histological necrosis observed
prior to extractions in patients, who receive bone-targeting agents. Oral Dis 26: 955-966.
11. Ristow O, et al (2021a). Wound closure and alveoloplasty after preventive tooth extractions in patients
with antiresorptive intake-A randomized pilot study. Oral Diseases 27:532-546.
12. Ristow O, et al (2021b). Diagnostic accuracy comparing OPG and CBCT in the detection of non-vital bone
changes before tooth extractions in patients with antiresorptive intake. Oral Diseases, 2021:00:1-11, 7
October 2

=== Ranked Population 9 (Extract #28, Patients) — Score: 9 ===
ound closure and alveoloplasty after preventive tooth extractions in patients
with antiresorptive intake-A randomized pilot study. Oral Diseases 27:532-546.
12. Ristow O, et al (2021b). Diagnostic accuracy comparing OPG and CBCT in the detection of non-vital bone
changes before tooth extractions in patients with antiresorptive intake. Oral Diseases, 2021:00:1-11, 7
October 2021.
13. Otto S, Pautke C, Van den Wyngaert T, et al (2018). Medication-related osteonecrosis of the jaw:
Prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treatment
Reviews 69:177-187.
14. Fu

=== Ranked Population 10 (Extract #39, Patients) — Score: 9 ===
a H, et al. Docetaxel and cisplatin in first line treatment of patients with
Row 18: nown primary cancer: a multicenter study of the anatolian society of medical oncology. Asian Pac J
Row 19: cer Prev. 2014;15(4):1581–1584.
Row 20: emori K, Ando M, Yunokawa M, et al. Irinotecan plus carboplatin for patients with carcinoma of Row 1: 
Row 2: 42. Hainsworth JD, Spigel DR, Clark BL, et al. Paclitaxel/carboplatin/etoposide versus
Row 3: gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a Row 1: review of 56 cases. Cancer 1987; 59:572.
Row 2: 44. Mukai H,

